Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atopix Therapeutics Appoints CMO

This article was originally published in Scrip

Executive Summary

Atopix Therapeutics Limited, a UK-based biotechnology company developing medicines to treat atopic dermatitis and severe asthma, has appointed Dr Andrew Zambanini chief medical officer. Zambanini has 25 years of experience in clinical medicine and the pharmaceutical industry. He has previously held positions at GlaxoSmithKline plc, where from 2003 until 2010 he held a variety of roles of increasing seniority up to vice-president level; Takeda Global R&D; Novartis AG; Kyowa Hakko Kirin UK; ProStrakan; Gilead Sciences; and Circassia.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel